Skip to main content
Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
183.63
-5.06 (-2.68%)
Mar 5, 2026, 4:00 PM EST - Market closed

Jazz Pharmaceuticals Revenue by Segment
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Neuroscience
2.88B 2.82B 2.75B 2.72B 2.70B 2.66B 2.63B 2.64B
Neuroscience Growth
6.68% 6.01% 4.40% 3.25% -0.35% -3.68% -5.92% -5.85%
Oncology
1.13B 1.08B 1.08B 1.08B 1.11B 1.09B 1.07B 1.04B
Oncology Growth
1.56% -0.93% 1.04% 3.77% 9.47% 13.26% 15.16% 15.23%

Oncology Revenue Breakdown
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Rylaze Enrylaze
402.92M 396.25M 395.16M 402.33M 410.85M 411.11M 417.19M 411.05M - - - - - -
Rylaze Enrylaze Growth
-1.93% -3.61% -5.28% -2.12% 4.22% 10.08% 21.95% 31.17% - - - - - -
Zepzelca
307.31M 295.20M 301.75M 308.25M 320.32M 316.00M 308.15M 297.45M - -
Zepzelca Growth
-4.06% -6.58% -2.08% 3.63% 10.63% 9.92% 10.13% 7.09% - -
Defitellio Defibtrotide
199.39M 198.17M 212.24M 209.55M 216.57M 210.00M 191.91M 192.60M
Defitellio Defibtrotide Growth
-7.93% -5.63% 10.59% 8.80% 17.70% 20.99% 9.48% 4.74%
Vyxeos
146.71M 165.23M 161.96M 160.12M 162.60M 156.26M 151.77M 142.82M
Vyxeos Growth
-9.77% 5.74% 6.71% 12.11% 10.24% 19.42% 15.78% 9.09%
Erwinaze
- - - - - - - - - - - - - - - - - - 146.10M 150.47M 147.14M

Neroscience Revenue Breakdown
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Xywav
1.66B 1.59B 1.55B 1.50B 1.47B 1.41B 1.35B 1.31B - - -
Xywav Growth
12.48% 13.00% 14.58% 14.67% 15.73% 15.77% 18.46% 24.80% - - -
Epidiolex
1.06B 1.05B 996.07M 991.44M 972.42M 938.00M 900.15M 855.28M - - - - -
Epidiolex Growth
8.92% 11.63% 10.66% 15.92% 15.02% 15.54% 13.32% 11.45% - - - - -
Xyrem
146.03M 157.54M 179.99M 206.83M 233.82M 291.25M 358.24M 455.83M
Xyrem Growth
-37.54% -45.91% -49.76% -54.63% -58.96% -59.01% -57.42% -52.07%
Sunosi
- - - - - - - - - - - - - - 63.03M 62.19M 57.91M 51.70M 41.56M 38.02M 28.33M
Sunosi Growth
- - - - - - - - - - - - - - 51.65% 63.58% 104.40% - - - -
Sativex
16.28M 19.95M 19.78M 21.55M 18.88M 18.84M 18.88M 15.31M - - - - -
Sativex Growth
-13.77% 5.87% 4.76% 40.80% -4.02% -2.13% 5.81% -20.21% - - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.